BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 9854206)

  • 1. [Imaging of somatostatin receptors in gastroenteropancreatic neuroendocrine tumors].
    Mure A; Lebtahi R; de Labriolle-Vaylet C; Askienazy S
    Gastroenterol Clin Biol; 1998 Oct; 22(10):809-18. PubMed ID: 9854206
    [No Abstract]   [Full Text] [Related]  

  • 2. [Scintigraphy of somatostatin receptors in the diagnosis and staging of neuroendocrine tumors of the digestive tract and pancreas].
    Banzo J; Abós MD; Prats E; García F; Razola P
    Rev Esp Med Nucl; 2000 Jun; 19(3):225-41. PubMed ID: 11062088
    [No Abstract]   [Full Text] [Related]  

  • 3. Somatostatin-receptor imaging of neuroendocrine gastroenteropancreatic tumors.
    Scherübl H; Bäder M; Fett U; Hamm B; Schmidt-Gayk H; Koppenhagen K; Dop FJ; Riecken EO; Wiedenmann B
    Gastroenterology; 1993 Dec; 105(6):1705-9. PubMed ID: 7902821
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Radiolabeled somatostatin analogs for radionuclide imaging and therapy in patients with gastroenteropancreatic neuroendocrine tumors.
    Bal CS; Gupta SK; Zaknun JJ
    Trop Gastroenterol; 2010; 31(2):87-95. PubMed ID: 20862981
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [The scintigraphy of somatostatin receptors in gastroenteropancreatic neuroendocrine tumors].
    Chiti A; Spinelli A; Bombardieri E
    Radiol Med; 1997 Oct; 94(4):362-70. PubMed ID: 9465244
    [No Abstract]   [Full Text] [Related]  

  • 6. Somatostatin receptor imaging with indium-111-pentetreotide in gastroenteropancreatic neuroendocrine tumors: safety, efficacy and impact on patient management.
    Jamar F; Fiasse R; Leners N; Pauwels S
    J Nucl Med; 1995 Apr; 36(4):542-9. PubMed ID: 7699439
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Somatostatin receptor-targeted radionuclide therapy in patients with gastroenteropancreatic neuroendocrine tumors.
    Kwekkeboom DJ; de Herder WW; Krenning EP
    Endocrinol Metab Clin North Am; 2011 Mar; 40(1):173-85, ix. PubMed ID: 21349418
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Positive somatostatin receptor scintigraphy correlates with the presence of somatostatin receptor subtype 2.
    John M; Meyerhof W; Richter D; Waser B; Schaer JC; Scherübl H; Boese-Landgraf J; Neuhaus P; Ziske C; Mölling K; Riecken EO; Reubi JC; Wiedenmann B
    Gut; 1996 Jan; 38(1):33-9. PubMed ID: 8566856
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Somatostatin receptor imaging for neuroendocrine tumors.
    de Herder WW; Kwekkeboom DJ; Feelders RA; van Aken MO; Lamberts SW; van der Lely AJ; Krenning EP
    Pituitary; 2006; 9(3):243-8. PubMed ID: 17001462
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Significance of false-positive findings of somatostatin receptor scintigraphy in diagnosis of neuroendocrine tumors of the gastroenteropancreatic system].
    Faiss S; Scherübl H; Bäder M; Fett U; Koppenhagen K; Wiedenmann B; Riecken EO
    Z Gastroenterol; 1994 May; 32(5):243-6. PubMed ID: 7915450
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gastroenteropancreatic tumor imaging with somatostatin receptor scintigraphy.
    Wiedenmann B; Bäder HM; Scherubl H; Fett U; Zimmer T; Hamm B; Koppenhagen K; Riecken EO
    Semin Oncol; 1994 Oct; 21(5 Suppl 13):29-32. PubMed ID: 7992077
    [No Abstract]   [Full Text] [Related]  

  • 12. Molecular imaging as in vivo molecular pathology for gastroenteropancreatic neuroendocrine tumors: implications for follow-up after therapy.
    Krenning EP; Valkema R; Kwekkeboom DJ; de Herder WW; van Eijck CH; de Jong M; Pauwels S; Reubi JC
    J Nucl Med; 2005 Jan; 46 Suppl 1():76S-82S. PubMed ID: 15653655
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nuclear medicine techniques for the imaging and treatment of neuroendocrine tumours.
    Teunissen JJ; Kwekkeboom DJ; Valkema R; Krenning EP
    Endocr Relat Cancer; 2011 Oct; 18 Suppl 1():S27-51. PubMed ID: 22005114
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular imaging of gastroenteropancreatic neuroendocrine tumors.
    Miederer M; Weber MM; Fottner C
    Gastroenterol Clin North Am; 2010 Dec; 39(4):923-35. PubMed ID: 21093764
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Results and potential of somatostatin receptor imaging in gastroenteropancreatic tract tumours.
    Chiti A; Briganti V; Fanti S; Monetti N; Masi R; Bombardieri E
    Q J Nucl Med; 2000 Mar; 44(1):42-9. PubMed ID: 10932600
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Radionuclide imaging of neurendocrine tumors: biological basis and diagnostic results].
    Genovese EA; Mallardo V; Rossi M; Vaccaro A; Raucci A; Della Vecchi N; Romano G; Califano T; Schillirò F
    Recenti Prog Med; 2013; 104(7-8):340-4. PubMed ID: 24042404
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Somatostatin receptor scintigraphy in the diagnosis of neuroendocrine gastroenteropancreatic tumors.
    Bäder M; Koppenhagen K
    Recent Results Cancer Res; 1996; 142():137-62. PubMed ID: 8893340
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Factor analysis of dynamic series (FADS) in somatostatin receptor imaging.
    Kolesnikov-Gauthier H; Huglo D; Nocaudie M; Marchandise X
    J Nucl Med; 1999 Jan; 40(1):33-9. PubMed ID: 9935053
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Gastroenteropancreatic neuroendocrine tumors: diagnosis and therapy in nuclear medicine].
    Haug AR; Bartenstein P
    Internist (Berl); 2012 Feb; 53(2):161-6. PubMed ID: 22231696
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Localization of gastroenteropancreatic neuroendocrine tumors with 111indium-pentetreotide scintigraphy.
    Pauwels S; Leners N; Fiasse R; Jamar F
    Semin Oncol; 1994 Oct; 21(5 Suppl 13):15-20. PubMed ID: 7992075
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.